Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranitidine, is still being currently sold.

Now, the drugmaker and co-defendants, including Pfizer, Sanofi, and Boehringer Ingelheim, have filed an ... to appeal directly to the higher court. Zantac was originated by GSK and launched ...

The complaints revolve around allegations that Zantac and other medicines containing ... which include Sanofi, Boehringer Ingelheim and Pfizer. In its latest statement, GSK reiterated its position ...

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... for consumer products with Boehringer Ingelheim and the purchase of Bioverativ ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the ...